Clinical trials: GLP - 1
Chronic Kidney Diseases
The Chronic Kidney Disease Adaptive Platform Trial Investigating Various Agents for Therapeutic Effect
CAPTIVATE is an international, multi-centre, Phase III, adaptive, platform, randomised controlled trial in people with chronic kidney disease (CKD).
- Trial name
- CAPTIVATE (NCT06058585)
- Testing
- Finerenone, Semaglutide
- Where
- 51 sites in Australia, India and 3 more
- Volunteers
- 2,000 people
- Sponsor
- The George Institute
Coronary Disease, Shock, Cardiogenic
GLP-1 and Hyperoxia for Organ Protection in Heart Surgery
Patients undergoing open heart surgery are at risk of suffering damage to the heart, brain and kidneys. This study is designed as a 2-by-2 randomized clinical trial with the purpose of investigating the organ protective effects…
- Conditions
- Coronary Disease, Shock, Cardiogenic, Renal Failure, Stroke
- Trial name
- GLORIOUS (NCT02673931)
- Testing
- Byetta (Lilly, Exenatide), Conoxia (AGA, oxygen), 20% Human Albumin
- Where
- Denmark
- Volunteers
- 1,400 people
- Sponsor
- Copenhagen University Hospital, Rigshospitalet
Reactive Hypoglycemia
Treatment With Sitagliptin for Reactive Hypoglycemia Secondary to Dysinsulinism
The purpose of this study is to determine whether sitagliptin is effective in the treatment of reactive hypoglycemia by dysinsulinism.
- Trial name
- NCT00847080
- Testing
- Sitagliptin phosphate
- Where
- Mexico
- Volunteers
- 20 people
- Sponsor
- Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran
Cardiometabolic Conditions
Effects of N-Acyl Taurines on Incretin Levels in Healthy Subjects
This study is an investigator-initiated, randomised, double-blind, placebo-controlled, cross-over human trial investigating the effect of arachidonoyl-taurine (C20:4-taurine) and oleoyl-taurine (C18:1-taurine) on GLP-1 secretion…
- Trial name
- NAT-INC (NCT07771166)
- Testing
- Arachidonoyl-taurine: First dose at 0 hours, Oleoyl-taurine: First dose at 0 hours, Liquid meal and second dose of OLE-T at 3 hours
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- University Hospital, Gentofte, Copenhagen
GLP - 1
Lifestyle Change Implementation Research Network at PRC at UMass Chan
The goal of this project is to study how well the Noom digital lifestyle program works for adults who are taking Glucagon-Like Peptide-1 receptor agonist (GLP-1) medications.
- Trial name
- LCIRN (NCT07481305)
- Testing
- Digital Lifestyle Coaching Program
- Where
- United States
- Volunteers
- 220 people
- Sponsor
- University of Massachusetts, Worcester
Blood Sugar; High, Overweight and Obesity
Effect of a Glucagon Like Peptide 1 (GLP1) Booster in Healthy Humans
BACKGROUND GLP1 booster (GB) was designed to stimulate the endogenous production of GLP1, which in turn releases insulin, controls blood glucose level, suppresses appetite and thus helps people lose weight.
- Conditions
- Blood Sugar; High, Overweight and Obesity, Fat Burn, Obesity
- Trial name
- NCT06333496
- Testing
- GLP-1 Booster (GB)
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Alpine Biotech LLC
GLP - 1, Obesity & Overweight
Combatting Muscle Loss in Obese Adult Patients on GLP-1 Medications Through Dietary Counseling and Exercise During Treatment Evaluates Whether a 12-week Exercise and Individualized Nutrition Program Can Reduce Muscle and Bone Loss and Improve Strength, Fitness, and Function in Obese Adults on GLP-1
Obesity remains a critical public health challenge and is associated with increased rates of morbidity, mortality, and chronic disease worldwide.
- Conditions
- GLP - 1, Obesity & Overweight, Muscle Loss, Exercise Intervention
- Trial name
- NCT07554417
- Testing
- Semaglutide, Dietary Counseling, Exercise
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- William Marsh Rice University